Roivant Sciences Ltd.
Total Trades
177
Buys
3
Sells
120
Largest Trade
$1M+
Insiders
15
Institutional Funds
327
Inst. Value
$1M+
Activist Filings
42
Insider Trades
| Insider | Title | Type | Value | Shares | Price | Date |
|---|---|---|---|---|---|---|
| Torti Frank | President and Vant… | SELL | $1M+ | 3.0M | $27.35 | Feb 24, 2026 |
| Torti Frank | President and Vant… | EXERCISE | $1M+ | 3.0M | $3.85 | Feb 24, 2026 |
| Venker Eric | President & Immuno… | EXERCISE | $500K+ | 200K | $3.85 | Feb 18, 2026 |
| Venker Eric | President & Immuno… | SELL | $1M+ | 200K | $26.49 | Feb 18, 2026 |
| MANCHESTER KEITH S | Director | SELL | $1M+ | 1.2M | $26.64 | Feb 14, 2026 |
| Gold Daniel Allen | Director | SELL | $1M+ | 1.2M | $26.64 | Feb 14, 2026 |
| QVT Financial LP | Insider | SELL | $1M+ | 1.2M | $26.64 | Feb 14, 2026 |
| Sukhatme Mayukh | President & CIO | EXERCISE | $1M+ | 652K | $12.68 | Feb 11, 2026 |
| Sukhatme Mayukh | President & CIO | SELL | $1M+ | 339K | $26.47 | Feb 11, 2026 |
| Venker Eric | President & Immuno… | EXERCISE | $500K+ | 200K | $3.85 | Jan 15, 2026 |
| Venker Eric | President & Immuno… | SELL | $1M+ | 200K | $21.92 | Jan 15, 2026 |
| Sukhatme Mayukh | President & CIO | EXERCISE | $1M+ | 3.2M | $12.68 | Jan 1, 2026 |
| Sukhatme Mayukh | President & CIO | SELL | $1M+ | 1.3M | $21.72 | Jan 1, 2026 |
| Pulik Richard | CFO | SELL | $1M+ | 407K | $22.43 | Dec 30, 2025 |
| Pulik Richard | CFO | EXERCISE | $1M+ | 260K | $3.85 | Dec 30, 2025 |
| Venker Eric | President & Immuno… | SELL | $1M+ | 275K | $22.47 | Dec 30, 2025 |
| Venker Eric | President & Immuno… | EXERCISE | $1M+ | 432K | $3.85 | Dec 30, 2025 |
| Sukhatme Mayukh | President & CIO | EXERCISE | $500K+ | 60K | $12.68 | Dec 20, 2025 |
| Sukhatme Mayukh | President & CIO | SELL | $500K+ | 27K | $23.09 | Dec 20, 2025 |
| Gold Daniel Allen | Director | SELL | $1M+ | 1.7M | $23.05 | Dec 19, 2025 |
| MANCHESTER KEITH S | Director | SELL | $1M+ | 1.7M | $23.05 | Dec 19, 2025 |
| QVT Financial LP | Insider | SELL | $1M+ | 1.7M | $23.05 | Dec 19, 2025 |
| Gline Matthew | CEO | SELL | $1M+ | 1.7M | $21.68 | Dec 18, 2025 |
| Gline Matthew | CEO | EXERCISE | $1M+ | 3.9M | $12.16 | Dec 18, 2025 |
| Ramaswamy Vivek | 10% Owner | SELL | $1M+ | 3.1M | $21.89 | Dec 16, 2025 |
| Ramaswamy Vivek | 10% Owner | EXERCISE | $1M+ | 7.4M | $12.68 | Dec 16, 2025 |
| Venker Eric | President & Immuno… | SELL | $1M+ | 200K | $20.85 | Dec 12, 2025 |
| Venker Eric | President & Immuno… | EXERCISE | $500K+ | 200K | $3.85 | Dec 12, 2025 |
| MANCHESTER KEITH S | Director | SELL | $1M+ | 1.3M | $20.23 | Nov 22, 2025 |
| Gold Daniel Allen | Director | SELL | $1M+ | 1.3M | $20.23 | Nov 22, 2025 |
| QVT Financial LP | Insider | SELL | $1M+ | 1.3M | $20.23 | Nov 22, 2025 |
| Ramaswamy Vivek | 10% Owner | SELL | $1M+ | 1.9M | $20.46 | Nov 17, 2025 |
| Venker Eric | President & Immuno… | EXERCISE | $500K+ | 200K | $3.85 | Nov 8, 2025 |
| Venker Eric | President & Immuno… | SELL | $1M+ | 200K | $20.22 | Nov 8, 2025 |
| Venker Eric | President & Immuno… | EXERCISE | $1M+ | 851K | $15.85 | Oct 18, 2025 |
| Venker Eric | President & Immuno… | SELL | $1M+ | 851K | $16.99 | Oct 18, 2025 |
| Venker Eric | President & Immuno… | SELL | $1M+ | 1.7M | $14.92 | Sep 24, 2025 |
| Venker Eric | President & Immuno… | EXERCISE | $1M+ | 1.6M | $3.85 | Sep 24, 2025 |
| Gline Matthew | CEO | BUY | $15K–$50K | 3K | $15.07 | Sep 18, 2025 |
| Ramaswamy Vivek | 10% Owner | SELL | $1M+ | 1.8M | $12.65 | Sep 5, 2025 |
| Venker Eric | President & Immuno… | SELL | $1M+ | 100K | $11.72 | Aug 23, 2025 |
| Venker Eric | President & Immuno… | EXERCISE | $100K–$500K | 100K | $3.85 | Aug 23, 2025 |
| Venker Eric | President & Immuno… | EXERCISE | $100K–$500K | 100K | $3.85 | Jul 24, 2025 |
| Venker Eric | President & Immuno… | SELL | $1M+ | 100K | $11.52 | Jul 24, 2025 |
| Venker Eric | President & COO | EXERCISE | $100K–$500K | 100K | $3.85 | Jun 25, 2025 |
| Venker Eric | President & COO | SELL | $1M+ | 100K | $11.45 | Jun 25, 2025 |
| Ramaswamy Vivek | 10% Owner | SELL | $1M+ | 1.1M | $11.46 | Jun 23, 2025 |
| Ramaswamy Vivek | 10% Owner | SELL | $1M+ | 748K | $11.30 | Jun 6, 2025 |
| Venker Eric | President & COO | EXERCISE | $1M+ | 1.4M | $3.85 | Jun 5, 2025 |
| Venker Eric | President & COO | SELL | $1M+ | 1.0M | $11.15 | Jun 5, 2025 |
Institutional Ownership
13F filings as of Dec 31, 2025 · 327 funds holding
| Fund | Shares | Value | Type |
|---|---|---|---|
| VANGUARD GROUP INC | 38.8M | $1M+ | SH |
| QVT Financial LP | 26.4M | $1M+ | SH |
| STATE STREET CORP | 17.4M | $1M+ | SH |
| SB INVESTMENT ADVISERS (UK) LTD | 16.4M | $1M+ | SH |
| Two Seas Capital LP | 9.8M | $1M+ | SH |
| Rubric Capital Management LP | 9.0M | $1M+ | SH |
| DIMENSIONAL FUND ADVISORS LP | 8.5M | $1M+ | SH |
| Patient Square Capital LP | 8.2M | $1M+ | SH |
| PERCEPTIVE ADVISORS LLC | 8.0M | $1M+ | SH |
| Assenagon Asset Management S.A. | 6.9M | $1M+ | SH |
| GEODE CAPITAL MANAGEMENT, LLC | 6.6M | $1M+ | SH |
| VIKING GLOBAL INVESTORS LP | 6.4M | $1M+ | SH |
| NORGES BANK | 5.2M | $1M+ | SH |
| Jefferies Financial Group Inc. | 3.5M | $1M+ | SH |
| ADAR1 Capital Management, LLC | 3.4M | $1M+ | SH |
| ADAR1 Capital Management, LLC | 3.4M | $1M+ | SH |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 3.2M | $1M+ | SH |
| Candriam S.C.A. | 2.5M | $1M+ | SH |
| JENNISON ASSOCIATES LLC | 2.4M | $1M+ | SH |
| Pictet Asset Management Holding SA | 2.3M | $1M+ | SH |
Activist & 5%+ Owners
SC 13D/13G filings — investors holding 5%+ of outstanding shares
SC 13G/A · Mar 6, 2026
10.3%
73.6M shares
SB Investment Advisers (UK) Limited
SC 13G/A · Feb 17, 2026
2.3%
16.4M shares
SC 13G/A · Feb 13, 2026
6.8%
48.4M shares
SC 13G/A · Feb 11, 2026
8.0%
55.5M shares
SC 13G/A · Feb 5, 2026
9.5%
65.8M shares
SC 13G/A · Nov 14, 2025
3.4%
23.6M shares
SB Investment Advisers (UK) Limited
SC 13G/A · Nov 14, 2025
5.8%
40.3M shares
SC 13G/A · Aug 14, 2025
5.0%
34.2M shares
SC 13G/A · Aug 14, 2025
4.3%
29.4M shares
SC 13G · Aug 7, 2025
5.5%
37.6M shares
SC 13G/A · Aug 6, 2025
8.2%
55.5M shares
SC 13G/A · May 15, 2025
11.6%
83.0M shares
SC 13G/A · May 15, 2025
11.2%
83.0M shares
SC 13G/A · May 15, 2025
6.4%
46.0M shares
SC 13G/A · Feb 14, 2025
9.2%
65.8M shares
SB Investment Advisers (UK) Limited
SC 13G/A · Feb 14, 2025
8.5%
62.1M shares
SC 13G/A · Nov 14, 2024
7.3%
54.1M shares
SC 13G/A · Nov 12, 2024
5.6%
41.7M shares
SC 13G · Nov 12, 2024
6.6%
49.1M shares
SC 13G/A · Nov 4, 2024
5.6%
41.7M shares
SC 13G/A · Apr 2, 2024
0.0%
0 shares
SC 13G/A · Mar 7, 2024
8.3%
66.7M shares
SC 13G/A · Feb 14, 2024
9.8%
81.5M shares
SC 13G/A · Feb 14, 2024
14.0%
112.5M shares
SC 13G/A · Feb 14, 2024
8.6%
69.4M shares
Dexcel Pharma Technologies Ltd.
SC 13G/A · Feb 14, 2024
0.6%
4.7M shares
SC 13G/A · Feb 13, 2024
9.8%
81.5M shares
SB Investment Advisers (UK) Limited
SC 13G/A · Feb 13, 2024
9.1%
73.0M shares
SC 13G/A · Feb 1, 2024
8.9%
71.3M shares
SC 13G/A · Jun 26, 2023
9.9%
75.2M shares
SC 13G/A · Feb 14, 2023
10.9%
81.8M shares
Dexcel Pharma Technologies Ltd.
SC 13G/A · Feb 14, 2023
0.6%
4.7M shares
SB Investment Advisers (UK) Limited
SC 13G/A · Feb 14, 2023
13.1%
95.0M shares
SC 13G/A · Feb 14, 2023
16.9%
122.5M shares
SC 13G/A · Feb 3, 2023
11.9%
86.4M shares
SC 13G · Feb 14, 2022
12.8%
0 shares
SC 13G · Feb 14, 2022
10.5%
74.4M shares
Integrated Core Strategies (US) LLC
SC 13G/A · Feb 14, 2022
0.0%
0 shares
SC 13G · Feb 14, 2022
18.7%
129.4M shares
SB Investment Advisers (UK) Limited
SC 13G · Feb 14, 2022
14.4%
99.4M shares
Dexcel Pharma Technologies Ltd.
SC 13G · Feb 10, 2022
0.1%
644K shares
SC 13G · Feb 1, 2022
12.5%
86.4M shares